VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Stock Comparison
Agilent Technologies, Inc. vs Amgen Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Agilent Technologies, Inc.
A · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Agilent Technologies, Inc.'s moat claims, evidence, and risks.
View A analysisAmgen Inc.
AMGN · Nasdaq Stock Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Comparison highlights
- Moat score gap: Amgen Inc. leads (70 / 100 vs 65 / 100 for Agilent Technologies, Inc.).
- Segment focus: Agilent Technologies, Inc. has 3 segments (41.9% in Agilent CrossLab); Amgen Inc. has 3 segments (80.1% in Core Innovative Medicines).
- Primary market structure: Competitive vs Competitive. Pricing power: Strong vs Moderate.
- Moat breadth: Agilent Technologies, Inc. has 5 moat types across 2 domains; Amgen Inc. has 5 across 3.
Primary market context
Agilent Technologies, Inc.
Agilent CrossLab
Laboratory services, compliance/maintenance, consumables and lab informatics across the lab workflow
Global
B2B (installed base labs across pharma, diagnostics, academia and applied markets)
Aftermarket services + consumables + informatics
41.9%
Amgen Inc.
Core Innovative Medicines
Branded biopharmaceutical therapies for common diseases (bone health, inflammation, oncology, cardiovascular and other specialty areas)
Global
Payers, providers, and pharmacies
Drug developer/manufacturer
80.1%
Side-by-side metrics
Moat coverage
Shared moat types
Agilent Technologies, Inc. strengths
Amgen Inc. strengths
Segment mix
Agilent Technologies, Inc. segments
Full profile >Life Sciences and Diagnostics Markets
Oligopoly
Agilent CrossLab
Competitive
Applied Markets
Oligopoly
Amgen Inc. segments
Full profile >Core Innovative Medicines
Competitive
Rare Disease Portfolio (Horizon + others)
Quasi-Monopoly
Biosimilars
Oligopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listLooking for expansion-stage stocks?
Proven models entering the expansion stage with unit economics that work.
View expansion-stage stocksCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.